SwitchPoint Bio Holding, Inc. operates a platform that combines precision epigenomics and artificial intelligence to analyze cellular biology from blood samples. The company provides biomarker discovery, patient stratification, and treatment response mechanism readouts to support drug development and clinical research.
Subscribe to see SwitchPoint Bio Holding, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
SwitchPoint Bio Holding, Inc. is a biotechnology company headquartered in United States. Its most recent funding round raised $5.3M in March 2026. Xcout tracks 8 named people at SwitchPoint Bio Holding, Inc., including Samuel Myllykangas (CEO).
As of 16 November 2026. Source: Xcout Intel.
2 more named people on record for SwitchPoint Bio Holding, Inc., with roles, board committees and tenure — see the full roster →
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $5.3M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of SwitchPoint Bio Holding, Inc.'s closest competitors — see the full list of competitors and alternatives →
Shift Bioscience is a biotechnology research company based in Cambridge, United Kingdom, that employs generative AI virtual cell models to understand gene activation and cellular reprogramming.
Cartography Biosciences is a biotechnology company that uses single-cell genomics, proteomics, machine learning, and computational biology to analyze massive datasets of healthy and cancerous human cells. Through its platforms, the company identifies new therapeutic targets and develops precision molecules designed to target tumors while sparing healthy tissue.
WittGen Inc. provides a virtual cell-to-patient profiling technology powered by single-cell generative AI for clinical leaders and biopharmaceutical researchers. The company's platform transforms archived bulk RNA samples and pathological image data into regulator-ready patient stratification insights and cellular-level biomarkers to de-risk clinical trials and accelerate oncology drug development.
Verge Genomics develops a proprietary AI and machine learning platform utilizing human brain data to transform neuroscience drug discovery and precision neurology. The company provides foundation models and analytical tools to pharmaceutical and biotechnology developers for target discovery, biomarker identification, and clinical trial patient stratification.
DeepSeq.AI is a biotechnology research company headquartered in California that builds protein interaction databases and utilizes artificial intelligence for drug discovery.
Noetik Inc. is an AI-native biotechnology company headquartered in South San Francisco, California, leveraging advanced machine learning methods for biological discovery.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about SwitchPoint Bio Holding, Inc.? Suggest a correction · Work at SwitchPoint Bio Holding, Inc.? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.